BDX

Becton, Dickinson and Company (BD) is a global medical technology company that manufactures and sells medical devices, instrument systems, and reagents used by healthcare institutions, physicians, life science researchers, and the general public. Founded in 1897, BD operates through three segments: BD Medical (medication management, diabetes care, pharmaceutical systems), BD Life Sciences (diagnostic systems, biosciences), and BD Interventional (surgery, peripheral intervention, urology and critical care). The company produces syringes, needles, infusion therapy products, insulin delivery devices, diagnostic systems, and surgical instruments. Headquartered in Franklin Lakes, New Jersey, BD serves healthcare providers across more than 190 countries through a combination of direct sales and distribution partners. The company has expanded through strategic acquisitions including C.R. Bard in 2017, significantly enhancing its interventional and surgical device portfolios. BD benefits from essential products, recurring revenue models, and innovation pipelines. The company continues to invest in automation, digital health, and expanding presence in emerging markets while managing integration complexities and competitive dynamics.